Two Sigma Investments, LP Inozyme Pharma, Inc. Transaction History

Two Sigma Investments, LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $98,560 - $182,361	-23,807 Reduced 44.33%	29,893 $228,000
Q4 2023 Feb 14, 2024	SELL	$2.71 - $4.5 $39,024 - $64,800	-14,400 Reduced 21.15%	53,700 $228,000
Q3 2023 Nov 14, 2023	SELL	$4.09 - $7.0 $71,521 - $122,409	-17,487 Reduced 20.43%	68,100 $286,000
Q2 2023 Aug 14, 2023	BUY	$4.93 - $6.74 $99,028 - $135,386	20,087 Added 30.67%	85,587 $476,000
Q1 2023 May 15, 2023	BUY	$1.3 - $5.73 $69,052 - $304,360	53,117 Added 428.95%	65,500 $375,000
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.82 $840 - $2,256	-800 Reduced 6.07%	12,383 $13,000
Q3 2022 Nov 14, 2022	BUY	$2.57 - $5.45 $33,880 - $71,847	13,183 New	13,183 $35,000
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.96 $34,931 - $65,059	-10,916 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.87 - $7.55 $42,244 - $82,415	10,916 New	10,916 $45,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $121M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.